Promising results from several groundbreaking clinical trials were presented at the ESMO Congress 2023, offering hope for patients with non-small cell lung cancer (NSCLC). These trials showcased the efficacy of new drugs that target molecular alterations in tumor cells, reducing the need for chemotherapy and improving outcomes for patients. NSCLC accounts for approximately 80% of all lung cancer cases.
Dr. Elene Mariamidze from Todua Clinic in Tbilisi, Georgia, emphasized that personalized medicine in NSCLC is entering a new era with the use of combinations of novel, targeted agents. The whole mutational burden of each patient needs to be identified at the time of diagnosis to plan the most effective and least toxic approach. The future of lung cancer care lies in finding the right combination of targeted treatments or chemotherapy with immunotherapy for each patient.
Studies presented at the ESMO Congress highlighted the use of a new combination of targeted drugs in patients with advanced or metastatic NSCLC who had an EGFR mutation, one of the most common tumor mutations. The combination showed significantly better progression-free survival (PFS) as a first-line treatment compared to the current standard of care for this mutation. In patients who had already progressed on the current standard of care, the new targeted drugs combined with chemotherapy significantly improved PFS compared to chemotherapy alone.
However, further research is needed to determine if this new combination leads to improved overall survival compared to current treatments. Additionally, the effects on patients with brain metastases need to be studied, as one of the newer EGFR-targeting agents used in these trials has shown good penetration of brain tissue.
These studies signify that patients now have a potential new drug combination for their treatment that works by targeting EGFR mutations and directing immune cells to destroy cancer cells. The fact that the combination performed better than the current standard of care, rather than just placebo, demonstrates tangible benefits of this new approach.
Results of these NSCLC studies also suggest that mutation-targeted treatments can reduce the need for chemotherapy in certain patients, including those with rarer tumor alterations that had limited targeted treatment options previously. This includes patients with operable, early-stage ALK-positive NSCLC, those with RET-mutated advanced NSCLC, and those with the less common and more difficult-to-treat EGFR mutation known as Exon 20 insertion, advanced NSCLC.
The data also support the addition of immunotherapy to chemotherapy in certain types of NSCLC, such as neoadjuvant treatment before surgery. This combination can help shrink tumors and indicate the likely response to further treatment after surgery. It has been observed that patients have a better prognosis if pre-surgical treatment leads to the disappearance of tumors on pathology reports after surgery.
Even for patients with advanced or metastatic NSCLC who have relapsed following previous treatments and can only receive chemotherapy, there is good news. The use of antibody-drug conjugates, which direct chemotherapy precisely at tumors by recognizing specific proteins commonly found in lung cancers, significantly improved progression-free survival compared to currently used chemotherapy.
This approach using antibody-drug conjugates is expected to make a significant difference for the majority of patients with advanced or metastatic NSCLC who have stopped responding to first and second-line treatments, regardless of whether they have targetable mutations. However, further research is needed to fully understand the side effects of this approach.
The next step for researchers is to determine the optimal sequence of treatments to achieve the best outcomes for patients. Understanding when and how to target different mutations, possibly including new targets, is crucial in establishing the ideal treatment plan for patients with advanced NSCLC. Combination therapies are likely to be necessary at different stages of lung cancer care, and further research is needed to determine the ideal treatment strategy for patients with extensive disease.
Overall, these groundbreaking clinical trials represent a significant step forward in the treatment of NSCLC, providing new hope and improved treatment options for patients. The era of personalized medicine and targeted therapies has the potential to revolutionize lung cancer care, offering better outcomes and improved quality of life for those affected by this devastating disease.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
